Advanced search
Publication Cover
Leukemia & Lymphoma Volume 59, 2018 - Issue 11
Submit an article Journal homepage
400
Views
7
CrossRef citations to date
0
Altmetric
Letter to the Editor

Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients

Stefano MolicaDepartment Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy; Correspondence[email protected]
,
Luciano LevatoDepartment Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy;
,
Rosanna MirabelliDepartment Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy;
,
Alessanda TedeschiUnità Operativa Complessa Ematologia, Grande Ospedale Metropolitano Niguarda, Milano, Italy
&
Mirella LentiniDepartment Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy;
Pages 2734-2736 | Received 25 Dec 2017, Accepted 27 Jan 2018, Published online: 21 Feb 2018

References

  • Varma G, Johnson TP, Advani RH. Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. Clin Adv Hematol Oncol. 2016;14:543–554.
  • Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
  • O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–1418.
  • Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18:241–250.
  • Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739–745.
  • Chang CS, Tsai CY, Yan SL. Hepatitis B reactivation in patients receiving targeted therapies. Hematology. 2017;22:592–598.
  • Tedeschi A, Frustaci AM, Mazzucchelli M, et al. Is HBV prophylaxis required during CLL treatment with ibrutinib? Leuk Lymphoma. 2017;58:2966–2968.
  • de Jésus Ngoma P, Kabamba B, Dahlqvist G, et al. Occult HBV reactivation induced by ibrutinib treatment: a case report. Acta Gastroenterol Belg. 2015;78:424–426.
  • Herishanu Y, Katchman H, Polliack A. Severe hepatitis B virus reactivation related to ibrutinib monotherapy. Ann Hematol. 2017;96:689–690.
  • http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Conclusion/human/003791/WC500235776.pdf
  • Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers. ClinicalTrials.gov Identifier: NCT02991638; 2016.
  • Law MF, Ho R, Cheung CK, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol. 2016;22:6484–6500.
  • Merli M, Rattotti S, Gotti M, et al. Antiviral therapies for managing viral hepatitis in lymphoma patients. Expert Opin Pharmacother. 2017;18:363–376.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.